» Articles » PMID: 25726090

Treatment Strategies and Outcomes of Bisphosphonate-related Osteonecrosis of the Jaw (BRONJ) with Characterization of Patients: a Systematic Review

Overview
Date 2015 Mar 2
PMID 25726090
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this systematic review was to answer the question: What are the treatments available for bisphosphonate-related osteonecrosis of the jaws (BRONJ) and their outcomes? A literature search of PubMed, Cochrane Library, and Web of Science databases was conducted in accordance with the PRISMA statement, search phrases were ('jaw osteonecrosis' OR 'bisphosphonate-related osteonecrosis' OR 'bisphosphonate osteonecrosis') AND ('treatment' OR 'outcomes'). Ninety-seven articles published between 2003 and February 2014 were reviewed. The studies reported 4879 cases of BRONJ. The mean age of the patients was 66.5 ± 4.7 years. The male to female ratio was 1:2. The mean duration of bisphosphonate (BP) administration was 38.2 ± 15.7 months. The quality of the publications was good, with some moderate and poor. Minimally invasive surgical treatment was the treatment most used. Medical treatment was also used. Adjunctive treatments included laser, growth factors, hyperbaric oxygen and ozone. The articles provided a broad range of outcome variables to assess the treatment of BRONJ and the outcomes of each treatment. Considerable heterogeneity was found regarding study design, sample size, and treatment modalities. Clinical trials with larger samples are required to provide sufficient information for each treatment modality to predict the outcomes of each treatment.

Citing Articles

Advanced progress of adipose-derived stem cells-related biomaterials in maxillofacial regeneration.

Zhang L, Yu Z, Liu S, Liu F, Zhou S, Zhang Y Stem Cell Res Ther. 2025; 16(1):110.

PMID: 40038758 PMC: 11881347. DOI: 10.1186/s13287-025-04191-y.


Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol.

Slowik L, Toton E, Nowak A, Wysocka-Slowik A, Okla M, Slebioda Z J Clin Med. 2025; 14(3).

PMID: 39941644 PMC: 11818125. DOI: 10.3390/jcm14030974.


Hyperbaric Oxygen Therapy as a Renewed Hope for Ischemic Craniomaxillofacial Diseases.

He C, Huang D, Liu L Healthcare (Basel). 2025; 13(2).

PMID: 39857164 PMC: 11764805. DOI: 10.3390/healthcare13020137.


Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS.

Bertoldo F, Eller-Vainicher C, Fusco V, Mauceri R, Pepe J, Bedogni A J Bone Oncol. 2025; 50():100656.

PMID: 39807373 PMC: 11728904. DOI: 10.1016/j.jbo.2024.100656.


The Effectiveness of Hyperbaric Oxygen Therapy on Older Patients With Medication-Related Osteonecrosis of the Jaws: A Case Series.

Kimura T, Kusano K, Sakata K, Sato J, Kitagawa Y Cureus. 2024; 16(9):e69226.

PMID: 39398845 PMC: 11470121. DOI: 10.7759/cureus.69226.